The Food and Drug Administration has authorized the first influenza vaccine using Moderna’s mRNA platform, promising a more effective flu shot for Americans aged 50 and above during the 2026-2027 season.
- First US flu vaccine using mRNA tech approved for ages 50+
- Shows 26.6% improvement over conventional shots
- Access for 65+ contingent on ongoing clinical trial
What happened
The FDA’s decision followed promising Phase 3 trial results showing the vaccine was 26.6% more effective than existing influenza vaccines, while maintaining comparable safety with mild side effects such as fatigue, headache, and nausea. This milestone reflects a significant innovation in flu vaccine development since traditional methods have remained largely unchanged for decades.
Why it feels good
Additionally, the use of mRNA vaccines has been well demonstrated in the COVID-19 pandemic, providing a strong safety and efficacy foundation for this new flu jab. Many people can feel reassured that the advancements in vaccine science are continuing to protect public health, potentially reducing the flu burden significantly.
What to enjoy or watch next
Keep an eye on expanding access to mFluvisa, especially as ongoing studies clarify best use for those over 65, a group particularly vulnerable to flu complications. Its availability is expected for the upcoming respiratory virus season starting in late 2026. Widespread adoption could reshape annual flu shot campaigns in the US.
Meanwhile, global developments such as Moderna’s combined COVID-19 and flu vaccine approved in Europe hint at future multi-virus mRNA shots that simplify immunization schedules. Staying informed about these innovations can help individuals and communities better prepare for flu seasons ahead.